Mathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infection

Simple item page
dc.contributor.advisorWitten, Gen_ZA
dc.contributor.authorMugwagwa, Tendaien_ZA
dc.date.accessioned2014-10-23T07:10:29Z
dc.date.available2014-10-23T07:10:29Z
dc.date.issued2005en_ZA
dc.descriptionIncludes bibliographical references.en_ZA
dc.description.abstractWhile most of Europe is affected by HIV-1 subtype B, sub-Saharan African is dominated by HIV-1 subtype C. Due to costs, most vaccine development is carried out Europe rather than sub-Saharan countries. However since the mechanisms of disease progression in HIV-1 subtype B may be different from those in HIV-1 subtype C, it is interesting to investigate if and how a dendritic cells based vaccine such as the one developed in France and tested on Brazilians (Lu et al, Nature; 2004) can be used on individuals in sub-Saharan Africa. To investigate this, mathematical models and sensitivity analysis techniques are used to understand the mechanisms of disease progression in two HIV-1 subtypes. These models are then extended to explore the ways in which the vaccine could be used to treat these different HIV-1 subtypes. It is found that the level of immune activation plays a large role in determining the mechanism of disease progression and can itself be a means to the development of AIDS. Furthermore, it is also shown that the dendritic cells based vaccine could reduce the viral load but not eliminate the virus resulting in a viral rebound. To maintain a low viral load, vaccination would have to be repeated. Unfortunately, repeated vaccination may lead to the overproduction of proinflamatory cytokines resulting in severe side effects. However this could be avoided by using a carefully planned treatment schedule. We conclude that the dendritic cells based vaccine can be used in individuals in either subtype B or subtype C region as long as the correct treatment schedule is followed.en_ZA
dc.identifier.apacitationMugwagwa, T. (2005). <i>Mathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infection</i>. (Thesis). University of Cape Town ,Faculty of Science ,Department of Mathematics and Applied Mathematics. Retrieved from http://hdl.handle.net/11427/8733en_ZA
dc.identifier.chicagocitationMugwagwa, Tendai. <i>"Mathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infection."</i> Thesis., University of Cape Town ,Faculty of Science ,Department of Mathematics and Applied Mathematics, 2005. http://hdl.handle.net/11427/8733en_ZA
dc.identifier.citationMugwagwa, T. 2005. Mathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infection. University of Cape Town.en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Mugwagwa, Tendai AB - While most of Europe is affected by HIV-1 subtype B, sub-Saharan African is dominated by HIV-1 subtype C. Due to costs, most vaccine development is carried out Europe rather than sub-Saharan countries. However since the mechanisms of disease progression in HIV-1 subtype B may be different from those in HIV-1 subtype C, it is interesting to investigate if and how a dendritic cells based vaccine such as the one developed in France and tested on Brazilians (Lu et al, Nature; 2004) can be used on individuals in sub-Saharan Africa. To investigate this, mathematical models and sensitivity analysis techniques are used to understand the mechanisms of disease progression in two HIV-1 subtypes. These models are then extended to explore the ways in which the vaccine could be used to treat these different HIV-1 subtypes. It is found that the level of immune activation plays a large role in determining the mechanism of disease progression and can itself be a means to the development of AIDS. Furthermore, it is also shown that the dendritic cells based vaccine could reduce the viral load but not eliminate the virus resulting in a viral rebound. To maintain a low viral load, vaccination would have to be repeated. Unfortunately, repeated vaccination may lead to the overproduction of proinflamatory cytokines resulting in severe side effects. However this could be avoided by using a carefully planned treatment schedule. We conclude that the dendritic cells based vaccine can be used in individuals in either subtype B or subtype C region as long as the correct treatment schedule is followed. DA - 2005 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2005 T1 - Mathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infection TI - Mathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infection UR - http://hdl.handle.net/11427/8733 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/8733
dc.identifier.vancouvercitationMugwagwa T. Mathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infection. [Thesis]. University of Cape Town ,Faculty of Science ,Department of Mathematics and Applied Mathematics, 2005 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/8733en_ZA
dc.language.isoengen_ZA
dc.publisher.departmentDepartment of Mathematics and Applied Mathematicsen_ZA
dc.publisher.facultyFaculty of Scienceen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.subject.otherMathematics and Applied Mathematicsen_ZA
dc.titleMathematical models of coreceptor usage and a dendritic cell-based vaccine during HIV-1 infectionen_ZA
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMScen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_sci_2005_mugwagwa_t.pdf
Size:
4.54 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Masters